Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Edwards Lifesciences (EW)

Edwards Lifesciences CFO Scott Ullem to transition from role by mid-2026

Neutral Impact 4 of 5 leadership Written later

Edwards Lifesciences said its Chief Financial Officer, Scott Ullem, has decided to transition from his role by mid-year 2026. The company is starting a search for a new CFO, and Ullem will stay on in an advisory role after the successor is appointed.

Key points

  • Scott Ullem, CFO, informed the company of his decision on October 30, 2025
  • Transition is planned for no later than mid-year 2026
  • Company is initiating a selection process to appoint a new CFO
  • Ullem will continue in an advisory role after a new CFO is appointed

The filing

CompanyEdwards Lifesciences (EW)
Form8-K, current report
Filed with the SECOct 30, 2025, 4:29 PM ET
Accession number0001193125-25-258662

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.